Kiromic BioPharma, Inc. has had a tricky time so far, having had to close a handful of clinical trials of its T-cell therapies owing to poor patient accrual and undergoing delisting from the NASDAQ last September. But now it has reported data on the first two patients in a clinical trial in lung cancer and Deltacel, an allogeneic gamma-delta T-cell product, looks promising.
Key Takeaways
- Kiromic BioPharma is developing a gamma-delta T-cell therapy for lung cancer
“We had high confidence about what this product will be able to deliver. And so far, we can say that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
